Event Type
Disclosure
Mandatory
Variant
8-K
Entry into a Material Definitive Agreement. On January 22, 2026, Oncotelic Therapeutics, Inc. (the “Company”) the Company entered into restricted stock agreemen
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. See Item 1.01
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description Incorporation by reference 10.1 Restricted Stock Award Filed herewith 104 Cover Page In